Baxter introduces HYLENEX, an FDA-approved human recombinant hyaluronidase for subcutaneous fluid administration in pediatrics patients. Unlike IV administration, HYLENEX is administered under the skin without the need to secure a vein for treatment initiation. HYLENEX temporarily makes the tissue beneath the skin more permeable, allowing fluids to be more readily absorbed into the blood vessels. HYLENEX has been shown to be safe and effective in infants and young children with mild to moderate dehydration.